PHVS Company Profile and Key Details

Pharvaris N.V. has 69.88 million shares outstanding. The public float is 39.67 million shares, elevated short interest at 1.98% of float. This equals 1.14 million shares. The short ratio is 2.09 days. Institutional investors hold 90.88% of the float. Insiders own 6.13%. Schikan Johannes Gerardus Christiaan Petrus holds 315.17 thousand shares, Modig Berndt has 130.62 thousand shares and Nassif David W. has 120.30 thousand shares. Over the past six months, insider transactions show net selling. They sold 235.90 thousand shares across 37 transactions.

Short-term trend indicators are bearishly aligned (SMA20 2.94%, SMA50 5.84%, SMA200 23.1%). The stock’s 14-day RSI is 56.74 (neutral), while the ATR of 1.45 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.03% below its high and over 143.27% above its low. Average 10-day trading volume of 1.40 million shares is significantly above the 3-month average of 616.58 thousand, indicating heightened recent market interest.

Pharvaris N.V. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.72. This means the shares are trading above this model’s fair value.

Pharvaris N.V. (NASDAQ:PHVS) closed at $37.74 USD, losing -$0.10 (-0.26%) from the previous close of $37.84. The stock is currently mid-range between its 52-week high and low $20.65 and $43.25. With a market capitalization of about $2.64 billion, Pharvaris N.V. is classified as a mid-cap and shows lower-than-market volatility (beta ~-2.32). Key stats such as the average daily volume over the past year has been around 624.77 thousand shares, trading with heavier-than-usual volume. Headquartered in Zug, ZH, Pharvaris N.V. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Berndt Modig, the company employs approximately 148 people and listed since February 04, 2021. Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.

Pharvaris N.V. generated EPS of -$3.22 over the past year. Five-year average earnings growth is -7.73%. Wall Street analysts project EPS growth of 3.74% annually over the next five years. The latest quarter delivered EPS of -$0.81. The next quarter is forecast at -$0.73. Next year's EPS is expected at $4.06. Analyst sentiment is bullish. Analyst rating data shows there are 15 Strong Buy ratings, 6 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $79.00 to $27.00. The high target offers 109.33% upside. The low target suggests -28.46% downside. The mean target is $51.48. This offers 36.41% upside. Pharvaris N.V. earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by 8.48%. The prior quarter beat by -17.06%. Over the last six quarters, Apple has recorded several small beats. These include 11.25% in May 13, 2025.

Pharvaris N.V. trades at a P/E ratio of -12.03, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.35 trading at moderately above to book value. The P/FCF stands at -14.54, also below market averages.

Pharvaris N.V. (NASDAQ:PHVS) shares are flat -5.55% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pharvaris N.V. trading at a premium to the broader market with a P/E of -12.03. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $37.38, suggesting -0.95% downside. Our AI forecast model points to short-term weakness (-4.74% over two weeks), a medium-term fall (-0.11% over three months), and a longer-term gain (12.51% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Pharvaris N.V. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.74%, with price expected at $35.95 by September 23, 2026, within a range of $34.92 to $37.07 3-Month Outlook: Projected fall of -0.11%, reaching $37.70 by December 08, 2026, with a range of $37.22 to $38.22. 1-Year Outlook: Projected gain of 12.51%, with price at $42.46 by September 09, 2027, within a range of $40.74 to $44.32.